DFV890 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Symptomatic Knee Osteoarthritis

Conditions

Symptomatic Knee Osteoarthritis

Trial Timeline

Sep 20, 2021 → Dec 23, 2024

NCT ID

NCT04886258

About DFV890 + Placebo

DFV890 + Placebo is a phase 2 stage product being developed by Novartis for Symptomatic Knee Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04886258. Target conditions include Symptomatic Knee Osteoarthritis.

What happened to similar drugs?

3 of 17 similar drugs in Symptomatic Knee Osteoarthritis were approved

Approved (3) Terminated (4) Active (10)

❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3

🔄ISV-305Sun PharmaceuticalPhase 3

🔄rabeprazole sodium + PlaceboEisaiPhase 3

🔄Esomeprazole + Matching placeboAstraZenecaPhase 3

🔄Pasireotide + OctreotideNovartisPhase 3

✅valsartanNovartisApproved

🔄Apixaban + Standard of carePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06031844	Phase 2	Completed	Oct 16, 2023	Dec 23, 2024	Coronary Heart Disease
NCT04886258	Phase 2	Completed	Sep 20, 2021	Dec 23, 2024	Symptomatic Knee Osteoarthritis

Competing Products

20 competing products in Symptomatic Knee Osteoarthritis

See all competitors

Product	Company	Stage	Hype Score
Sodium hyaluronate + placebo injection	Daiichi Sankyo	Phase 3	32
ISV-305	Sun Pharmaceutical	Phase 3	40
rabeprazole sodium + Placebo	Eisai	Phase 3	40
Verinurad + Febuxostat + Dapagliflozin	AstraZeneca	Phase 2	35
RDEA3170 + Febuxostat + Benzbromarone	AstraZeneca	Phase 1/2	32
Esomeprazole + Matching placebo	AstraZeneca	Phase 3	40
Omalizumab + Omalizumab + Placebo	Novartis	Phase 2	35
Pasireotide + Octreotide	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 2	35
valsartan	Novartis	Approved	43
Atorvastatin - Cholestyramine - Sitosterol	Pfizer	Pre-clinical	26
Epoetin biosimilar	Pfizer	Pre-clinical	26
Apixaban + Standard of care	Pfizer	Phase 3	40
Azithromycin plus chloroquine	Pfizer	Phase 3	32
Mavacamten	Bristol Myers Squibb	Approved	50
Aficamten + Placebo	Sanofi	Phase 3	44
Vandetanib 300 mg	Sanofi	Pre-clinical	26
REGN7508 + Acetylsalicylic Acid (ASA) + Placebo	Regeneron Pharmaceuticals	Phase 3	47
Rivaroxaban + Placebo	Bayer	Phase 3	37
Droxidopa capsules + Placebo capsules	Lundbeck	Approved	40